Skip to content

Crossover RCT of TAMER Lenses in Myopia Control

A Randomized, Crossover Controlled Trial of the Effect of TAMER Lenses Versus Single Vision Lenses on Myopic Progression in Myopic Children

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06329986
Enrollment
120
Registered
2024-03-26
Start date
2024-02-24
Completion date
2026-01-31
Last updated
2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia, Progressive

Brief summary

This study is a prospective, randomized, crossover clinical trial with a planned proposed enrollment of 120 Chinese male and female subjects aged 6-12 years without systemic or ocular diseases to follow up their cycloplegic equivalent spherical lens power and other relevant indices in order to determine the role of TAMER lenses in myopia control as compared to singlie vision lenses.

Interventions

DEVICETAMER Lens Spectacle

Regular daily wear of TAMER lens spectacle

DEVICESV lenses

SV lenses

Sponsors

Shanghai Eye Disease Prevention and Treatment Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Race: Chinese children and adolescents. * Age 6-12 years, gender unrestricted. * Cycloplegic refraction SER: -0.75DS\ -5.0DS in both eyes. * Best corrected visual acuity of both eyes reaches 0.8 (0.00 logMAR). * Cylinder power and astigmatism are no more than 1.5D. * During the study period, willing to wear glasses provided by the researcher only and without additional interventions. * Willing to be randomly assigned. * Able to sign an informed consent form with the accompaniment and understanding of parents or guardians.

Exclusion criteria

* Allergic or intolerant to medications used for cycloplegia. * Received any nearsightedness treatment such as atropine, rigid gas permeable contact lens, bifocal/progressive lens, red light therapy, or acupuncture within half a year before the study. * Diagnosed with any eye disease other than nearsightedness, including strabismus, corneal diseases, conjunctival or eyelid damage or other conditions (such as keratoconus, herpes simplex keratitis, etc.). * History of eye surgery (including strabismus correction surgery). * Eye or systemic diseases that might be associated with nearsightedness or its progression, such as Marfan syndrome, retinopathy of prematurity, diabetes, etc. * Anatomical or dermatological factors that may interfere with the wearing of spectacle frames. * Other reasons that the researcher deems inappropriate for the participant to be included in the study, such as excessively high expectations for the effectiveness of defocus lenses, or plans to use other nearsightedness intervention strategies simultaneously with the study.

Design outcomes

Primary

MeasureTime frameDescription
Spherical Equivalent change6 monthscycloplegic SE change

Secondary

MeasureTime frame
Axial Length change6 months
Spherical Equivalent change12 months

Countries

China

Contacts

Primary ContactXiangui He
dllcrco@shsyf.com021-62982727-817

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026